ClinicalTrialsFinder
RecruitingPhase 4NCT07538570

Evaluation of Pain Treatment After Total Knee Arthroplasty

A Phase 4, Double-blind, Sequential Cohort Study of Pain Treatment and Recovery After Total Knee Arthroplasty

Sponsor

Vertex Pharmaceuticals Incorporated

Enrollment

60 participants

Start Date

Apr 24, 2026

Study Type

INTERVENTIONAL

Conditions

Pain

Summary

The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Suzetrigine for people with pain. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSuzetrigine

Tablets for oral administration.

DRUGPlacebo

Placebo matched to SUZ for oral administration

Locations(2)

Legent Orthopedic and Spine Hospital

Bellaire, Texas, United States

Memorial Hermann Village Office

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07538570

Related Trials

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

NCT072582902 locations

Sociocultural & Biobehavioral Influences on Pain Expression and Assessment

NCT032585801 location

Clinical and Scientific Assessment of Pain and Painful Disorders

NCT027070291 location

Foot Reflexology and Ta-VNS for Symptom Management in Head and Neck Cancer During CCRT

NCT077116261 location

Testing the Pain Clinical Practice Guideline

NCT0585899611 locations